Haploidentical transplants using ex vivo T-cell depletion

详细信息    查看全文

• 作者：Massimo F. Martelli^a ; ^{mfmartelli39@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Franco Aversa^b
• 关键词：T-cell&ndash ; depleted haplo-transplant ; T-cell&ndash ; replete haplo-transplant ; GvL effect ; Tregs adoptive immunotherapy
• 刊名：Seminars in Hematology
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：53
• 期：4
• 页码：252-256
• 全文大小：329 K

文摘

Allogeneic hematopoietic stem cell transplantation (HSCT) is the best post-remission therapy for patients with acute leukemia (AL) at high risk of relapse. Advantages of having a family member as donor include: no undue delay in obtaining the graft; choice of best donor with regards to natural killer (NK) alloreactivity and cytomegalovirus (CMV) status from a panel of candidate family members; easy access to post-transplant cellular therapies like donor lymphocyte infusions and opportunity for a second graft from the original donor, or another family member in case of graft failure. This review will explore how the biological obstacles to HLA-haploidentical (haplo)-HSCT were overcome and how transplant modalities have evolved over time to potentiate the graft-versus-leukemia (GvL) effect in the absence of graft-versus-host disease (GvHD).